



Partnerships under Horizon Europe



Lessons Learned

from Horizon 2020 Interim Evaluation



Support breakthrough innovation



Create more impact through mission-orientation and citizens' involvement



Rationalise partnerships' landscape



Reinforce openness



Strengthen international cooperation



Encourage participation



Key Novelties

in Horizon Europe

European Innovation Council

EU Missions

New approach to partnerships

Open science policy

Extended association possibilities

Spreading Excellence



New approach to European Partnerships

New generation of objective-driven and more ambitious partnerships in support of agreed EU policy objectives

Key Features

- **Strategic orientation**
- **Systemic approach**
- **Simple architecture and toolbox**
- **Common set of criteria for the life-cycle**

CO-PROGRAMMED

Based on Memoranda of Understanding/contractual arrangements; implemented independently by the partners and by Horizon Europe

CO-FUNDED

Based on a joint programme agreed and implemented by partners; commitment of partners for financial and in-kind contributions

INSTITUTIONALISED

Based on long-term dimension and need for high integration; partnerships based on Art 185/187 of TFEU and the EIT legal acts for 2021-2027

Overview of 49 candidate European Partnerships

HORIZON EUROPE PILLAR II - Global challenges & European industrial competitiveness

CLUSTER 1: Health	CLUSTER 4: Digital, Industry & Space	CLUSTER 5: Climate, Energy & Mobility	CLUSTER 6: Food, Bioeconomy, Agriculture, ...
Innovative Health Initiative	Key Digital Technologies	Clean Hydrogen	Circular Bio-based Europe
Global Health Partnership	Smart Networks & Services	Clean Aviation	Rescuing Biodiversity to Safeguard Life on Earth
Transformation of health systems	High Performance Computing	Single European Sky ATM Research 3	Climate Neutral, Sustainable & Productive Blue Economy
Chemicals risk assessment	European Metrology (Art. 185)	Europe's Rail	Water4All
ERA for Health	AI-Data-Robotics	Connected and Automated Mobility (CCAM)	Animal Health & Welfare*
Rare diseases*	Photonics	Batteries	Accelerating Farming Systems Transitions*
One-Health Anti Microbial Resistance*	Made in Europe	Zero-emission waterborne transport	Agriculture of Data*
Personalised Medicine*	Clean steel – low-carbon steelmaking	Zero-emission road transport	Safe & Sustainable Food System*
Pandemic Preparedness* <i>Co-funded or co-programmed</i>	Processes4Planet	Built4People	
	Global competitive space systems**	Clean Energy Transition	
		Driving Urban Transitions	

- Institutionalised Partnerships (Art 185/7)
- Institutionalised Partnerships / EIT KICs
- Co-Programmed
- Co-Funded

* Calls with opening dates in 2023-24
 ** Calls with opening dates not before 2022

PILLAR III - Innovative Europe

EIT (KNOWLEDGE & INNOVATION COMMUNITIES)	SUPPORT TO INNOVATION ECOSYSTEMS
InnoEnergy	Innovative SMEs
Climate	
Digital	
Food	
Health	
Raw Materials	
Manufacturing	
Urban Mobility	
Cultural and Creative Industries	

CROSS-PILLARS II & III

European Open Science Cloud



Health Cluster Partnership Candidates

Institutional Partnerships (Article 185 and Article 187 TFEU)

2021 - Innovative Health Initiative (ex-IMI2)

2021 - EU-Africa Global Health (ex-EDCTP2)

Co-funded Partnerships

2021/22 - Partnership on Assessment of Risk of Chemicals (PARC)

2022/23 - Transforming Health and Care systems

2023/24 - Personalised Medicine

2023/24 - Rare Diseases

2024/25 - One Health AMR

2024/25 - Fostering an ERA for Health research

Pandemic preparedness?



Innovative Health Initiative (IHI)



Building on the Innovative Medicine Initiative (2008 – now)

- IMI is world's largest public-private partnership in life sciences, between the EU and pharmaceutical industry (represented by EFPIA)
- **Budget: over €5 billion, half of which from EU, the other half provided mostly in-kind by EFPIA companies, as well as by Associated Partners**
- Objectives
 - improve the current drug development process.
 - develop diagnostic & treatment biomarkers
 - reduce time to clinical proof of concept
 - increase success rate in clinical trials of priority medicines (WHO)
 - develop new therapies for diseases with high unmet need (e.g. Alzheimer's) & limited market incentives (e.g. AMR)
 - reduce failure rate of vaccine candidates

Success story: role in the development of J&J Ebola vaccine approved for use in July 2020

Why Innovative Health Initiative?

- COVID-19 has demonstrated that the public and private sectors must work together to address the immediate public health challenges.
- IHI builds on its predecessor, the Innovative Medicines Initiative (IMI), but has a significantly broadened scope, enlarged partner composition and revised objectives:
 - ✓ Integrating various technologies (pharmaceutical, medtech, biotech, imaging, vaccines) for better prevention, diagnosis and treatment;
 - ✓ Better responding to public health needs;
 - ✓ Better addressing the requirements of patients and health care professionals;
 - ✓ More openness to new ideas from external stakeholders.
- The new partner composition addresses the main finding of IMI2 interim evaluation: “enable the active engagement of other industry sectors with the pharmaceutical industry to capitalise on their expertise in the development of new health care interventions”.
- Cross-sectoral collaboration will be at the heart of IHI.

Innovative Health Initiative (IHI)

European public-private partnership in precompetitive R&I between the EU and health industries:

- Pharmaceutical companies (EFPIA) including the vaccine sector (Vaccines Europe)
- Medical imaging, radiotherapy, health ICT and electro-medical companies (COCIR)
- Medical technology companies (MedTechEurope)
- Biotechnology companies (EuropaBio)

Budget: 2.4 billion EUR over 7 years

1.2 billion EUR from the EU (Horizon Europe)

1 billion EUR from industry, mostly in-kind

200 million EUR from contributing partners

More info: <https://www.imi.europa.eu/about-imi/innovative-health-initiative>



Innovative Health Initiative (IHI)

Specific objectives:

- 1) understanding of the determinants of health and priority disease areas;
- 2) integrate fragmented R&I efforts, to enable improved prediction, prevention, interception, diagnosis, treatment and management of diseases, meeting the needs of end-users;
- 3) demonstrate the feasibility of people-centred, integrated health care solutions;
- 4) exploit the full potential of digitalisation and data exchange in health care;
- 5) enable the development of new and improved methodologies and models for a comprehensive assessment of the added value of innovative and integrated health care solutions.

Innovative Health Initiative (IHI) - features

- Integration of various actors along the health R&I value chain
- Strengthened collaboration across technology sectors
- Flexibility as regards disease areas, as long as addressing an unmet public health need
- Covering prevention, diagnosis, treatment, disease management of diseases affecting the EU population
- Contribution to Europe's Beating Cancer Plan, the Pharmaceutical Strategy and the Industrial Strategy for Europe
- The funded project should remain at pre-competitive level, not to deliver products or services directly in health care systems or on the market

IHI and cancer

Activities of potential relevance for cancer

- 1) better understanding of health and disease mechanisms at molecular level
 - 2) research on biomarkers (for disease diagnosis, progression and treatment)
 - 3) research on new diagnostic approaches, including imaging
 - 4) research on new therapeutic strategies
 - 5) methodologies for the integration of health technologies coming from different industry sectors
 - 6) pre-standardisation activities
- Contribution of IHI to Europe's Beating Cancer Plan is established in the founding legislation

Expected formal start: late November - early December 2022
First call launch: Q2 2022





Transforming Health and Care Systems (THCS)



Towards a cofunded European partnership on Transforming Health and Cares Systems (THCS)

- Key problem drivers:
 - Demographic changes.
 - Poor uptake of technological innovations.
 - Climate changes, environmental factors and globalisation.
 - Changes in political and social landscape.
- The opportunity offered by the THCS co-funded partnership: To pool a critical mass of European/national/regional scientific resources to research, develop and test organisational, service and policy innovations. The context-specific knowledge and evidence will inform health policies and facilitate uptake of innovations, as well as their scaling-up and transfer to other countries and regions.
- The General Objective: to ensure the transition towards more sustainable, resilient, innovative and high quality people-centred health and care systems.

THCS state of play October 2021

- Under Destination 4: Ensuring access to innovative, sustainable and high-quality health care in the EU
- Commission contribution: max €100 mn
- 24 Member States and Associated Countries have expressed their interest
- Coordinator has been chosen by the MSs/ACs (September 2021): Italy
- The partnership will build on the strategic research agenda developed by the Horizon2020-funded support action TO-REACH, will draw on the expertise and experiences from the Member States and network of regions involved in the European Innovation Partnership on Active and Healthy Ageing (EIP-AHA), and the Second 'Active and Assisted Living' programme (AAL2).
- Contact Commission: RTD-HS-PARTNERSHIP@ec.europa.eu
- Contact the Core Group: THCSpartnership@gmail.com

Timeline

December 2019

First meeting between
EC & MSs/ACs

June 2020

Draft proposal
published

October 2020

Commitments
communicated

July 2021

First draft SRIA

December 2021

SRIA finalised

April 2022

Proposal
submitted, inc.
first AWP

January 2023

Launch of
partnership
and first calls

The partnership will run for seven years!

THCS & cancer

- Problem drivers (among others):
 - Demographic change and pressure on health and care systems
 - Technological development and the need for implementation research
- Specific objectives (among others):
 - To improve the ability of relevant health and care actors to take up innovative solutions, including organisational, service and policy innovations
 - To establish a platform for connection and coordination of relevant stakeholders to develop the ecosystems allowing for a swift scaling up and transfer of successful innovations to different health and care systems
- *“this Partnership will search for synergies with other EU and Horizon Europe initiatives (such as EIC, other clusters, the other partnerships and Missions, in particular the Cancer Mission)”*

